Liisa Bayko
Stock Analyst at Evercore ISI Group
(3.58)
# 785
Out of 5,180 analysts
81
Total ratings
53.73%
Success rate
24.87%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Liisa Bayko
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RARE Ultragenyx Pharmaceutical | Maintains: Outperform | $37 → $34 | $19.38 | +75.44% | 10 | Feb 18, 2026 | |
| CRSP CRISPR Therapeutics AG | Maintains: Outperform | $62 → $74 | $45.75 | +61.75% | 3 | Feb 13, 2026 | |
| VRTX Vertex Pharmaceuticals | Maintains: Outperform | $475 → $530 | $433.07 | +22.38% | 20 | Jan 23, 2026 | |
| ENTA Enanta Pharmaceuticals | Maintains: Outperform | $20 → $12 | $12.18 | -1.48% | 5 | Sep 15, 2025 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Outperform | $280 → $515 | $317.36 | +62.29% | 2 | Sep 11, 2025 | |
| SVRA Savara | Maintains: In-Line | $3 → $2 | $5.14 | -61.09% | 5 | May 28, 2025 | |
| TVTX Travere Therapeutics | Maintains: Outperform | $33 → $45 | $27.25 | +65.14% | 5 | Feb 12, 2025 | |
| BCRX BioCryst Pharmaceuticals | Maintains: Outperform | $10 → $12 | $9.33 | +28.62% | 5 | Jan 13, 2025 | |
| EDIT Editas Medicine | Maintains: Outperform | $7 → $5 | $2.23 | +124.22% | 5 | Dec 16, 2024 | |
| KNSA Kiniksa Pharmaceuticals International, | Maintains: Outperform | $30 → $35 | $45.75 | -23.50% | 4 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $405 → $360 | $510.68 | -29.51% | 9 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: In-Line | $7 → $2 | $3.66 | -45.36% | 3 | May 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $14 → $25 | $3.02 | +727.81% | 1 | Jan 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $35 | $6.27 | +458.21% | 1 | Nov 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $24 | $38.86 | -38.24% | 1 | Jun 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Outperform | $30 | $15.08 | +98.94% | 1 | Nov 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Market Outperform | $10 | $4.29 | +133.10% | 1 | Feb 5, 2020 |
Ultragenyx Pharmaceutical
Feb 18, 2026
Maintains: Outperform
Price Target: $37 → $34
Current: $19.38
Upside: +75.44%
CRISPR Therapeutics AG
Feb 13, 2026
Maintains: Outperform
Price Target: $62 → $74
Current: $45.75
Upside: +61.75%
Vertex Pharmaceuticals
Jan 23, 2026
Maintains: Outperform
Price Target: $475 → $530
Current: $433.07
Upside: +22.38%
Enanta Pharmaceuticals
Sep 15, 2025
Maintains: Outperform
Price Target: $20 → $12
Current: $12.18
Upside: -1.48%
Alnylam Pharmaceuticals
Sep 11, 2025
Maintains: Outperform
Price Target: $280 → $515
Current: $317.36
Upside: +62.29%
Savara
May 28, 2025
Maintains: In-Line
Price Target: $3 → $2
Current: $5.14
Upside: -61.09%
Travere Therapeutics
Feb 12, 2025
Maintains: Outperform
Price Target: $33 → $45
Current: $27.25
Upside: +65.14%
BioCryst Pharmaceuticals
Jan 13, 2025
Maintains: Outperform
Price Target: $10 → $12
Current: $9.33
Upside: +28.62%
Editas Medicine
Dec 16, 2024
Maintains: Outperform
Price Target: $7 → $5
Current: $2.23
Upside: +124.22%
Kiniksa Pharmaceuticals International,
Oct 30, 2024
Maintains: Outperform
Price Target: $30 → $35
Current: $45.75
Upside: -23.50%
Aug 8, 2024
Maintains: Outperform
Price Target: $405 → $360
Current: $510.68
Upside: -29.51%
May 16, 2024
Maintains: In-Line
Price Target: $7 → $2
Current: $3.66
Upside: -45.36%
Jan 18, 2023
Maintains: Outperform
Price Target: $14 → $25
Current: $3.02
Upside: +727.81%
Nov 23, 2021
Initiates: Outperform
Price Target: $35
Current: $6.27
Upside: +458.21%
Jun 8, 2021
Initiates: Outperform
Price Target: $24
Current: $38.86
Upside: -38.24%
Nov 24, 2020
Reinstates: Outperform
Price Target: $30
Current: $15.08
Upside: +98.94%
Feb 5, 2020
Upgrades: Market Outperform
Price Target: $10
Current: $4.29
Upside: +133.10%